Compare Amer Sports Inc (AS) vs Sana Biotechnology Inc (SANA) Price & Performance

Amer Sports (AS) trades at $33.47, down 7.46% over 24 hours amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.38 surpassing expectations. Revenue growth remains strong at 32% year-over-year in Q1 2026, and the company raised its full-year guidance. Analyst consensus is overwhelmingly bullish with a $58.67 price target, though technical indicators suggest near-term weakness.

The outlook is positive given robust fundamentals and upward earnings revisions, but risks include execution on growth targets and market volatility. The current price presents a potential entry point relative to analyst targets, though investors should monitor the upcoming Q2 2026 earnings report on August 18, 2026, for confirmation of continued momentum.

SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.